Lexology October 10, 2024
Ropes & Gray LLP

The drug development process is inefficient and expensive. Pharmaceutical companies generally spend 10 to 15 years to bring a drug to market1 and can expect to spend anywhere from $1 billion to $2 billion over this timespan.2 Drug development has become more expensive over time, with costs doubling every nine years.3

Artificial intelligence (“AI”) can potentially address these inefficiencies by reducing costs, especially at the drug discovery and design stage. The drug discovery process may involve identifying a biological target responsible for the disease, identifying molecules that interact with this target, and developing lead molecules into preclinical testing. AI can potentially accelerate this process by sifting through large quantities of data to identify targets and then designing drugs that bind...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: AI (Artificial Intelligence), Biotechnology, Govt Agencies, Pharma, Pharma / Biotech, Technology
Microsoft’s 10 new AI agents strengthen its enterprise automation lead
Learning the Language of Life with A.I.
How Payers are Using AI to Deny Claims and Dent Provider Revenue
Generative AI Is Helping To Clear Up Brain Fog
Getting started with AI agents (part 2): Autonomy, safeguards and pitfalls

Share This Article